|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon alfa-2a (PEG-IFN) treatment stopping rules in chronic hepatitis B (CHB) are clinically desirable.
|
30865588 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of HBV mutants in the BCP region determined by NGS at baseline was associated with poor treatment outcome in patients with HBeAg-positive CHB receiving PEG-IFN.
|
31359359 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
|
29456079 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated.
|
29879024 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination with ETV and PEG-IFN could be an option for treatment of CHB patients especially in those with baseline HBsAg levels of less than 3.5 log U/ml.
|
29438098 |
2018 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that SNP rs4646536 in the CYP27B1 gene is a predictive factor of response to PEG-IFN therapy in Thai patients with CHB.
|
28291736 |
2017 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Th17-related gene polymorphisms were linked to HBeAg<sup>+</sup> CHB susceptibility, and rs4711998, rs763780 and rs12508721 were associated with sustained responses to PEG-IFNa-2α.
|
28595093 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was aimed at comparing its usefulness with quantitative HBsAg in patients with HBeAg-positive CHB receiving PEG-IFN therapy.
|
26678018 |
2016 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate the association between single nucleotide polymorphisms (SNPs) G-201A of the IP-10 gene and treatment response to pegylated interferon (PEG-IFN) in patients with hepatitis B e antigen (HBeAg)-positive CHB.
|
26376789 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible involvement of estrogen receptor α (ESR1) in responding to pegylated interferon alpha-2a (PEG IFNα-2a) therapy in chronic hepatitis B (CHB) patients.
|
26485345 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-negative are pegylated interferon alfa-2a (PEG-IFN) for 48 weeks or nucleos(t)ide analogues (NAs).
|
27793564 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, ss469415590 genotypes were not associated with response to PEG-IFN in Thai patients with HBeAg-positive and HBeAg-negative CHB.
|
26225703 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to characterize the immunological features responsible for improved treatment responses with pegylated interferon (PEG-IFN)-α2a in entecavir (ETV)-suppressed patients with CHB.
|
25814467 |
2015 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether IPS1 polymorphisms affect peginterferon alpha (PEG-IFN) efficacy in chronic hepatitis B (CHB) patients using a tag- single nucleotide polymorphism (SNP) approach.
|
25640825 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate whether IL28B polymorphisms could affect the treatment response to peginterferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients in the Chinese Han population.
|
24517415 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the effect of IL28-B polymorphisms in the treatment with pegylated-interferon (PEG-IFN) of patients with CHB.
|
24316030 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) loss was observed in 1 patient (2.5%); 56 patients (88%) showed at the time of diagnosis of CHB another infectious diseases that required specific treatment before PEG-IFN; this treatment was also affected by an higher incidence of side-effects (>50%).
|
24631900 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the limited efficacy is the main factor restricting the use of PEG-IFNα in CHB and therefore identifying the predictors of response is of great clinical importance.
|
24373089 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The occurrence of anti-IFN antibodies is associated with non-response to PEG-IFN in chronic hepatitis C. This study investigated the association between anti-IFN antibodies and response to PEG-IFN in CHB.
|
24296674 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline HBsAg level in combination with HBV DNA may become an effective predictor for guiding optimal therapy with PEG-IFN-α2b against HBeAg-positive CHB.
|
25009392 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that a sequential approach is a promising strategy of treatment in patients with CHB and high viremia in comparison with PEG-IFN monotherapy.
|
23490378 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of these features, new therapeutic trials based upon a combination of PEG-IFN and third generation NUC such as entecavir and tenofovir, in both naïve and NUC-exposed patients, are ongoing to further increase the rates of HBsAg seroclearance, which remains the 'ideal end-point' in all HBeAg-negative CHB subjects.
|
23286860 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB.
|
23553752 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
On-treatment HBsAg decline during PEG-IFN therapy for HBeAg-positive CHB depends upon HBV genotype.
|
22267464 |
2012 |